- Home
- THCH vs BMEA Comparison
THCH vs BMEA Comparison
Compare THCH & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- BMEA
- Stock Information
- Founded
- THCH 2018
- BMEA 2017
- Country
- THCH China
- BMEA United States
- Employees
- THCH N/A
- BMEA N/A
- Industry
- THCH Blank Checks
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- THCH Finance
- BMEA Health Care
- Exchange
- THCH Nasdaq
- BMEA Nasdaq
- Market Cap
- THCH 73.0M
- BMEA 65.8M
- IPO Year
- THCH N/A
- BMEA 2021
- Fundamental
- Price
- THCH $2.93
- BMEA $1.44
- Analyst Decision
- THCH
- BMEA Strong Buy
- Analyst Count
- THCH 0
- BMEA 11
- Target Price
- THCH N/A
- BMEA $27.60
- AVG Volume (30 Days)
- THCH 6.2K
- BMEA 703.1K
- Earning Date
- THCH 06-09-2025
- BMEA 05-05-2025
- Dividend Yield
- THCH N/A
- BMEA N/A
- EPS Growth
- THCH N/A
- BMEA N/A
- EPS
- THCH N/A
- BMEA N/A
- Revenue
- THCH $190,593,061.00
- BMEA N/A
- Revenue This Year
- THCH N/A
- BMEA N/A
- Revenue Next Year
- THCH N/A
- BMEA N/A
- P/E Ratio
- THCH N/A
- BMEA N/A
- Revenue Growth
- THCH N/A
- BMEA N/A
- 52 Week Low
- THCH $2.15
- BMEA $1.29
- 52 Week High
- THCH $6.00
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- THCH 57.60
- BMEA 39.69
- Support Level
- THCH $2.71
- BMEA $1.29
- Resistance Level
- THCH $2.93
- BMEA $1.52
- Average True Range (ATR)
- THCH 0.19
- BMEA 0.14
- MACD
- THCH 0.02
- BMEA 0.01
- Stochastic Oscillator
- THCH 90.91
- BMEA 28.17
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. It is also the operator and developer of Popeyes brand in Mainland China. The firm has two reportable segments; Tim Hortons which generates key revenue, and Popeyes. The company's revenue is derived from its operations in the PRC.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.